Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Clinical Trial

— CYCLONE 1  

Official title:

CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04408924
• Other study ID #: 17583
• Secondary ID: I3Y-MC-JPCY2020-
• Status: Completed
• Phase: Phase 2
• Start date: January 20, 2021
• Est. completion date: June 2, 2023

Study information

• Verified date: November 2023
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: June 2, 2023
• Est. primary completion date: April 27, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant).

• Participant must have disease spread to soft tissue that is measurable.

• Participant must have documented evidence of progressive disease by PSA test or imaging.

• Participant must have previously received at least one of the following treatment:

abiraterone acetate, apalutamide, darolutamide or enzalutamide.

• Participant must have previously received chemotherapy with docetaxel and cabazitaxel.

• Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research.

• Participant must have good physical functioning ability and adequate organ function.

Exclusion Criteria:

• Participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens.

• Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors.

• Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.

• Participants must not have, or suspected to have, brain metastasis.

• Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.

Related Conditions & MeSH terms

• Metastatic Castration-Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Abemaciclib
Administered orally

Locations

Country	Name	City	State
France	Centre Leon Berard	Lyon Cedex 08
France	Institut Paoli-Calmettes	Marseille
France	Hopital Europeen Georges Pompidou	Paris
France	Institut Claudius Regaud	Toulouse cedex 9
France	Gustave Roussy	Villejuif Cedex
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Institut Catala d'Oncologia	L'Hospitalet de Llobregat	Barcelona
Spain	Hospital General Universitario Gregorio Maranon	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario Ramon y Cajal	Madrid
Spain	Corporacion Sanitaria Parc Tauli	Sabadell	Barcelona
United States	University of Utah - Huntsman Cancer Institute	Salt Lake City	Utah
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])	ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator.; ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.	From Date of First Dose until Objective Progression (Up To 12.8 Months)
Secondary	Radiographic Progression-Free Survival (rPFS)	The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.	From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months)
Secondary	Overall Survival (OS)	OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.	From Date of First Dose until Date of Death from Any Cause (Estimated Up To 28 Months)
Secondary	Duration of Response (DoR)	DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.	CR or PR to Disease Progression or Death Due to Any Cause (Estimated Up to 28 Months)
Secondary	Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])	The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.	From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months)
Secondary	Time to Prostate-Specific Antigen (PSA) Progression	Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (>=) 25 percentage (%) increase and an absolute increase of >=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.	From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Secondary	Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)	The PSA response rate is defined as the percentage of participants with a reduction in PSA level =50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.	From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Secondary	Time to Symptomatic Progression	Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.	From Date of First Dose until Symptomatic Progression (Up to 12.8 Months)
Secondary	Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib	PK: Cmax,ss of abemaciclib is reported.	Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Secondary	PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib	PK: Cmin,ss of abemaciclib is reported.	C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Secondary	PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)	PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.	C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Secondary	PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)	PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.	C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Secondary	Baseline Ki-67 Expression by Immunohistochemistry (IHC)	Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry.; Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities =1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.	Baseline

External Links

•   Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)